⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22862786 | 0.86 | — | — | |
| SCHEMBL20840584 | 0.78 | — | — | |
| SCHEMBL7824207 | 0.77 | HCAR2 (0.42) | — | |
| SCHEMBL11100217 | 0.73 | — | — | |
| SCHEMBL1586293 | 0.73 | — | — | |
| SCHEMBL4734595 | 0.71 | HSP90AB1 (0.35) | — | |
| SCHEMBL7048553 | 0.71 | — | — | |
| SCHEMBL11841571 | 0.69 | — | — | |
| SCHEMBL9048605 | 0.69 | MAPK1 (0.36) | — | |
| SCHEMBL10726274 | 0.69 | CYP3A4 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106496140-A | The synthetic method of 5 fluorine of medical raw material, 2 methyl, 4,6 dihydroxy-pyrimidine | 无锡乾浩生物医药有限公司 | 2017-03-15 | — | — | CN | disclosed |
| EP-2217226-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| EP-2217226-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20140323476-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| US-20140323476-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| EP-2785348-A1 | PEPTIDE DEFORMYLASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2014-10-08 | — | — | EP | disclosed |
| WO-2014141181-A1 | PROCESS FOR PREPARING PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LIMITED (GB) | 2014-09-18 | — | — | WO | disclosed |
| WO-2013082388-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013082388-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-06-06 | — | — | WO | disclosed |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-02-21 | — | — | US | disclosed |
| EP-1968956-A2 | CALCIUM CHANNEL ANTAGONISTS | Icagen, Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| EP-1968596-A2 | CALCIUM CHANNEL ANTAGONISTS | Icagen, Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| US-20070197523-A1 | CALCIUM CHANNEL ANTAGONISTS | ICAGEN, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070173504-A1 | CALCIUM CHANNEL ANTAGONISTS | ICAGEN, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| WO-2007075852-A2 | CALCIUM CHANNEL ANTAGONISTS | ICAGEN, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007073497-A2 | CALCIUM CHANNEL ANTAGONISTS | ICAGEN, INC. (US) | 2007-06-28 | — | — | WO | disclosed |
| EP-1730122-A2 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005095357-A2 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-13 | — | — | WO | disclosed |
| EP-0210025-A2 | 5-Substituted-6-aminopyrimidine derivatives, composition and uses | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-01-28 | — | — | EP | disclosed |
| US-4617393-A | CONGESITIVE HEART FAILURE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1986-10-14 | — | — | US | disclosed |